DDInter1042 DDInter528
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect.
Dextropropoxyphene {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Dextropropoxyphene {u} (Compound) resembles {v} (Compound) Disopyramide
Dextropropoxyphene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Dextropropoxyphene {u} (Compound) resembles {v} (Compound) Levacetylmethadol
Dextropropoxyphene {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Dextropropoxyphene {u} (Compound) upregulates {v} (Gene) UBQLN2
Dextropropoxyphene {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Dextropropoxyphene {u} (Compound) downregulates {v} (Gene) RUVBL1
Dextropropoxyphene {u} (Compound) causes {v} (Side Effect) Asthenia
Dextropropoxyphene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Dextropropoxyphene may lead to a major life threatening interaction when taken with Tamoxifen
Dextropropoxyphene (Compound) resembles Disopyramide (Compound)
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Dextropropoxyphene (Compound) resembles Levacetylmethadol (Compound)
Dextropropoxyphene (Compound) binds CYP3A7-CYP3A51P (Gene)
Dextropropoxyphene (Compound) upregulates UBQLN2 (Gene)
Dextropropoxyphene (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Dextropropoxyphene (Compound) downregulates RUVBL1 (Gene)
Dextropropoxyphene (Compound) causes Asthenia (Side Effect)
Dextropropoxyphene may cause a minor interaction that can limit clinical effects when taken with Metronidazole